Cause and duration of heart failure may impact on the response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction

被引：0
|
作者：
Mandal, Amit K. J. [1 ]
Missouris, Constantinos G. [1 ,2 ]
机构：
[1] Frimley Hlth NHS Fdn Trust, Dept Cardiol, Wexham Pk Hosp, Slough, Berks, England
[2] Univ Cyprus, Dept Cardiol, Sch Med, Nicosia, Cyprus
来源：
JOURNAL OF CARDIOVASCULAR MEDICINE | 2021年 / 22卷 / 03期
关键词：
D O I：
10.2459/JCM.0000000000001111
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：233 / 234
页数：2
相关论文
共 50 条
  • [21] Clinical benefit of sacubitril-valsartan in patients with heart failure with reduced ejection fraction
    Spinoni, Enrico Guido
    Lio, Veronica
    Degiovanni, Anna
    Erbetta, Riccardo
    Marino, Paolo
    Patti, Giuseppe
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N101 - N101
  • [22] Use and Benefit of Sacubitril/Valsartan in Elderly Patients with Heart Failure with Reduced Ejection Fraction
    Roca, Luis Nieto
    Garcia, Marcelino Cortes
    German, Jorge Balaguer
    Becerra, Antonio Jose Bollas
    Otero, Jose Maria Romero
    Chapel, Jose Antonio Esteban
    Lopez, Carlos Rodriguez
    Lazaro, Ana Maria Pello
    Urquia, Mikel Taibo
    Tunon, Jose
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [23] The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension
    Takigami, Yu
    Ishii, Shunsuke
    Eda, Yuko
    Yazaki, Mayu
    Fujita, Teppei
    Iida, Yuichiro
    Ikeda, Yuki
    Nabeta, Takeru
    Oikawa, Jun
    Koitabashi, Toshimi
    Ako, Junya
    HEART AND VESSELS, 2023, 38 (11) : 1337 - 1343
  • [24] Real world experience of sacubitril and valsartan in patients with heart failure with reduced ejection fraction
    Ganesananthan, S.
    Shah, N.
    Shah, P.
    Phillips, J.
    Elsayed, H.
    Yousef, Z.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 222 - 222
  • [25] The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension
    Yu Takigami
    Shunsuke Ishii
    Yuko Eda
    Mayu Yazaki
    Teppei Fujita
    Yuichiro Iida
    Yuki Ikeda
    Takeru Nabeta
    Jun Oikawa
    Toshimi Koitabashi
    Junya Ako
    Heart and Vessels, 2023, 38 : 1337 - 1343
  • [26] Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation
    Bayard, Geoffrey
    Da Costa, Antoine
    Pierrard, Romain
    Romeyer-Bouchard, Cecile
    Guichard, Jean Baptiste
    Isaaz, Karl
    IJC HEART & VASCULATURE, 2019, 25
  • [27] Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction
    Pericas, Pere
    Mas-Llado, Caterina
    Ramis-Barcelo, Maria Francisca
    Valadron, Isabel
    Noris Mora, Marta
    Pasamar Marquez, Lucia
    Gonzalez Colino, Rosa
    Forteza Alberti, Jose Francisco
    Peral Disdier, Vicente
    Rossello, Xavier
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2021, 28 (02) : 167 - 175
  • [28] Use of phenomapping to determine response of treatment by sacubitril/valsartan in patients with heart failure with reduced ejection fraction
    Godet, M.
    Raitiere, O.
    Chopra, H.
    Guignant, P.
    Fauvel, C.
    Gaudin, K.
    Eltchaninoff, H.
    Beuer, F.
    EUROPEAN HEART JOURNAL, 2019, 40 : 735 - 735
  • [29] Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan
    Diez-Villanueva, Pablo
    Vicent, Lourdes
    de la Cuerda, Francisco
    Esteban-Fernandez, Alberto
    Gomez-Bueno, Manuel
    de Juan-Baguda, Javier
    Manuel Iniesta, Angel
    Ayesta, Ana
    Rojas-Gonzalez, Antonio
    Bover-Freire, Ramon
    Iglesias, Diego
    Garcia-Aguado, Marcos
    Angel Perea-Egido, Jesus
    Salamanca, Jorge
    Martinez-Selles, Manuel
    CARDIOLOGY, 2020, 145 (05) : 275 - 282
  • [30] Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
    Rex C. Liu
    American Journal of Cardiovascular Drugs, 2018, 18 : 473 - 482
12345